Arjun V. Balar, MD, discusses combination treatment with pembrolizumab (Keytruda) and axitinib (Inlyta) in the first-line setting for metastatic RCC.
In this video, Arjun V. Balar, MD, discusses the use of the immune checkpoint inhibitor pembrolizumab (Keytruda) for the treatment of metastatic renal cell carcinoma. Balar is associate professor of medicine at the NYU Grossman School of Medicine and genitourinary medical oncology program director at NYU Langone’s Perlmutter Cancer Center, New York.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.